SCOL.ST
Price:
$0.0041
Market Cap:
$656.73K
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
Industry
Biotechnology
IPO Date
2018-11-08
Stock Exchange
STO
Ticker
SCOL.ST
According to Scandion Oncology A/S’s latest financial reports and current stock price. The company's current Enterprise Value is -11962272.60. This represents a change of -171.53% compared to the average of 16.72M of the last 4 quarters.
The mean historical Enterprise Value of Scandion Oncology A/S over the last ten years is 111.92M. The current -11962272.60 Enterprise Value has changed -1168.82% with respect to the historical average. Over the past ten years (40 quarters), SCOL.ST's Enterprise Value was at its highest in in the September 2020 quarter at 620.75M. The Enterprise Value was at its lowest in in the September 2022 quarter at -23975100.19.
Average
111.92M
Median
63.83M
Minimum
-12619000.00
Maximum
466.25M
Discovering the peaks and valleys of Scandion Oncology A/S Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.11%
Maximum Annual Enterprise Value = 466.25M
Minimum Annual Increase = -115.25%
Minimum Annual Enterprise Value = -12619000.00
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | -12619000.00 | -115.25% |
| 2023 | 82.73M | 2.11% |
| 2022 | 3.74M | -97.95% |
| 2021 | 182.73M | -60.81% |
| 2020 | 466.25M | 402.62% |
| 2019 | 92.76M | 166.25% |
| 2018 | 34.84M | -22.44% |
The current Enterprise Value of Scandion Oncology A/S (SCOL.ST) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
24.62M
5-year avg
144.57M
10-year avg
111.92M
Scandion Oncology A/S’s Enterprise Value is less than ExpreS2ion Biotech Holding AB (publ) (7.10M), less than Hansa Biopharma AB (publ) (3.55B), less than FluoGuide A/S (356.34M), less than Saniona AB (publ) (2.46B), less than Oncopeptides AB (publ) (1.13B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 7.10M | $42.48M | |
| 3.55B | $2.88B | |
| 356.34M | $517.56M | |
| 2.46B | $2.76B | |
| 1.13B | $1.15B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Scandion Oncology A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Scandion Oncology A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Scandion Oncology A/S's Enterprise Value?
What is the highest Enterprise Value for Scandion Oncology A/S (SCOL.ST)?
What is the 3-year average Enterprise Value for Scandion Oncology A/S (SCOL.ST)?
What is the 5-year average Enterprise Value for Scandion Oncology A/S (SCOL.ST)?
How does the current Enterprise Value for Scandion Oncology A/S (SCOL.ST) compare to its historical average?